Boston Scientific Reports Q1 2026 Financial Results
Boston Scientific Corporation announced its financial results for the first quarter of 2026, reporting net sales of $5.203 billion, an increase of 11.6% compared to the previous year. The company also reported a GAAP net income of $1.341 billion, translating to $0.90 per share. The adjusted EPS was $0.80, up from $0.75 year-over-year. Key growth was noted in the cardiovascular and neuromodulation segments. The company has provided guidance for full-year sales growth of approximately 7.0 to 8.5% and adjusted EPS of $3.34 to $3.41.
MARLBOROUGH, Mass., April 22, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026, growing 11.6 percent on a reported basis and 9.4 percent on an operational1 and organic2 basis, all compared to the prior…